Philip (Phil) Powell Purchases 50,000 Shares of INOVIQ Ltd (ASX:IIQ) Stock

INOVIQ Ltd (ASX:IIQGet Free Report) insider Philip (Phil) Powell acquired 50,000 shares of the company’s stock in a transaction on Monday, March 10th. The stock was acquired at an average cost of A$0.35 ($0.22) per share, for a total transaction of A$17,500.00 ($11,006.29).

INOVIQ Price Performance

The company has a quick ratio of 9.52, a current ratio of 7.07 and a debt-to-equity ratio of 2.02. The firm has a market cap of $47.40 million, a P/E ratio of -6.02 and a beta of 2.04.

INOVIQ Company Profile

(Get Free Report)

INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample.

Read More

Receive News & Ratings for INOVIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INOVIQ and related companies with MarketBeat.com's FREE daily email newsletter.